We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





SARS-CoV-2 Found in 100% of Infected Patients' Stools Suggests COVID-19 Could Be a Gut Infection

By HospiMedica International staff writers
Posted on 11 Sep 2020
A new study of symptomatic patients who tested positive for COVID-19 has found SARS-CoV-2 in 100% of fecal samples, suggesting that COVID-19 could be a gut infection and a potential new transmission route.

The study by Progenabiome (Ventura, CA, USA) in collaboration with the Centre for Digestive Diseases (CDD Sydney, Australia) also showed COVID-19 mutations, providing insights into the SARS-CoV-2 virus, its evolution and strains, based on data from the stools of patients. More...


The fecal samples showed SARS-Cov-2 infective virus in all nasopharyngeal positive patients using a more sensitive method, suggesting potential for fecal-oral transmission. Different mutations were found among those in which SARS-CoV-2 was detected by whole genome sequencing.

"Since the outbreak of COVID-19, I felt it was important to look at patient's stools because of the prevalence of ACE2 receptors in the GI tract. PCR testing by definition looks at and copies a small portion of genetic information; because of this, it only shows a segment of the virus which may or may not be significant. More importantly, it doesn't help guide the therapy," said Sabine Hazan, MD, CEO of Progenabiome. "Alternatively, whole genome sequencing provides a much more comprehensive view, allows us to better understand the virus and its various mutations, and it serves as a better diagnostic tool to assess evolution of this virus that may more accurately distinguish if the virus disappears after treatment."

Related Links:
Progenabiome
Centre for Digestive Diseases (CDD)



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.